# Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

> **NCT00403325** · PHASE1 · COMPLETED · sponsor: **Vitreous -Retina- Macula Consultants of New York** · enrollment: 9 (actual)

## Conditions studied

- Central Serous Chorioretinopathy

## Interventions

- **DRUG:** rhuFab V2 [ranibizumab] ( Lucentis )

## Key facts

- **NCT ID:** NCT00403325
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2008-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403325, "Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00403325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*